UltraGreen's Partnership Aims to Reshape Global Cardiac Monitoring

NEW YORK, NY – April 21, 2026 – UltraGreen Cardiac Technologies, a division of digital health firm UltraGreen.ai, today announced a major strategic partnership with biosensor pioneer LifeSignals. The agreement positions UltraGreen to lead the global distribution of LifeSignals' advanced wearable cardiac monitors, a move set to significantly expand access to critical diagnostic technology for hospitals, cardiology practices, and diagnostic facilities worldwide.

A MedTech Power Play in a Crowded Market

This partnership marks a significant strategic pivot for UltraGreen.ai, a company primarily known as a leader in fluorescence-guided surgery. By entering the multi-billion dollar cardiac monitoring market, the firm is leveraging its digital health expertise to diversify its portfolio and tackle a new, high-growth vertical. The move places UltraGreen in direct competition with established players like iRhythm Technologies and Philips' BioTelemetry division, signaling a bold ambition to capture a share of the rapidly evolving MedTech landscape.

The agreement focuses on the global distribution of LifeSignals' 1AXe and 2AYe cardiac monitoring biosensors, which will be integrated with UltraGreen's UbiqVue™ Holter software platform. This creates an end-to-end solution that UltraGreen will commercialize under its own brand, offering flexible models ranging from direct hardware sales to fully integrated services complete with cloud software and ECG technician support.

"This partnership reflects our commitment to building clinically relevant, data-driven platforms that address real capacity challenges in healthcare systems globally," said Ravi Sajwan, CEO of UltraGreen, in the announcement. This statement underscores a broader corporate strategy focused on leveraging data to solve pressing healthcare problems. By expanding from surgical guidance to continuous remote monitoring, UltraGreen.ai is building a comprehensive digital health ecosystem designed to improve patient outcomes across different care pathways.

The Technology Redefining the Heartbeat

At the core of this partnership is LifeSignals' innovative biosensor technology. The 1AXe and 2AYe devices are single-use, water-resistant patches worn on the chest. They are designed to continuously collect high-fidelity, 2-channel ECG data for up to eight days, a significant improvement in both duration and data quality over many traditional Holter monitors.

What sets this technology apart in a competitive field is its approach to data handling. Unlike some widely used patches that store data locally and must be physically returned for analysis—a process that introduces delays—LifeSignals' biosensors transmit encrypted data wirelessly to a secure cloud server in near real-time. This capability, enabled by a proprietary System-on-Chip (SoC) platform, allows for faster analysis and reporting.

This "untethered healthcare" model, as LifeSignals describes it, means clinicians can potentially receive diagnostic reports within hours instead of days or weeks. The process is further accelerated by the UbiqVue™ platform's FDA-cleared algorithms, which provide automated data analysis. For healthcare providers, this translates into dramatic workflow efficiencies, faster clinical decision-making, and the potential for earlier intervention when a serious arrhythmia is detected. For patients, the lightweight, disposable patches offer greater comfort and convenience, improving compliance during the critical monitoring period.

An Arsenal Against a Global Health Crisis

The timing of this partnership is critical, as it directly confronts the escalating global burden of cardiovascular disease. As the leading cause of morbidity worldwide, conditions like atrial fibrillation and other arrhythmias affect millions, placing immense and sustained pressure on cardiology services and diagnostic capacity. An aging global population and the rising prevalence of chronic diseases are only expected to exacerbate this challenge.

Expanding access to continuous, wearable cardiac monitoring is a key strategy in combating this trend. Intermittent or brief ECGs often miss sporadic arrhythmias. By providing several days of uninterrupted data, devices like the LifeSignals biosensors dramatically increase the probability of detecting these events. Early detection is crucial for initiating preventative treatments, such as anticoagulation therapy for atrial fibrillation, which can significantly reduce the risk of stroke.

UltraGreen Cardiac Technologies aims to deploy these solutions across a spectrum of healthcare settings, from large hospital systems and specialized cardiology practices to independent diagnostic testing facilities (IDTFs). By enabling more efficient and accessible monitoring, the partnership promises to not only improve diagnostic yield but also help optimize the use of limited healthcare resources, allowing clinicians to focus on patients who need the most urgent care.

Navigating the Path to Global Adoption

With the global cardiac monitoring market projected to reach over $26 billion by 2029, the commercial opportunity is vast. However, success depends on navigating a complex web of international regulations and reimbursement policies. Here, the partnership appears well-positioned. LifeSignals has already secured key regulatory milestones, including multiple FDA 510(k) clearances in the United States, CE Mark and the more stringent EU MDR certifications in Europe, and HSA approval in Singapore.

These existing clearances provide UltraGreen with a significant head start, reducing the time and expense required to enter major international markets. The company's plan to offer flexible commercial models is another strategic advantage. By allowing healthcare systems to either purchase the hardware directly and manage their own data interpretation or opt for an integrated service model with software and technician support, UltraGreen can cater to a wider range of customer needs and operational capabilities.

This adaptability will be crucial for penetrating diverse healthcare economies with varying reimbursement structures. As UltraGreen Cardiac Technologies begins its global rollout, its ability to combine LifeSignals' validated, near real-time monitoring technology with a scalable and flexible business model will be the ultimate test of its ambition to make a lasting impact on cardiac care. The alliance represents a powerful fusion of advanced hardware, intelligent software, and strategic market access, creating a formidable new force in the fight against heart disease.